RT @synovialjoints: Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a hi

Dr. Antoni Chan @synovialjoints Nov 14, 2022

Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 t.co/lFXl2ywbZe #ACR22 @RheumNow

Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study - ACR Meeting Abstracts

Article Drug Safety

Increased VTE Risk with Baricitinib

Jack Cush, MD Jun 16, 2026

The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.

Article Rheumatoid Arthritis

Risk of Venous Thromboembolism in Rheumatoid Arthritis

Jack Cush, MD Aug 19, 2026

RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; Rheumatology, 2026).